Extended model‐based designs for more complex dose‐finding studies

We discuss extensions of model-based designs, such as the continual reassessment method, for use in dose-finding studies. Rather than work with a single model to carry out the design and analysis of a dose-finding study we indicate how the use of several models can greatly increase flexibility. We can appeal to established results on Bayesian model choice and this device makes the inferential problem essentially straightforward. The greater flexibility enables us to take on board many different kinds of added complexity. Examples include extended models to deal with subject heterogeneity, extended models to take account of different treatment schedules and extended models to tackle the problem of partial ordering.

[1]  Shyamal D Peddada,et al.  Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.

[2]  J O'Quigley,et al.  Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method , 2011, Statistics in medicine.

[3]  John O'Quigley,et al.  Continual Reassessment Method for Ordered Groups , 2003, Biometrics.

[4]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[5]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[6]  Sarah Zohar,et al.  Retrospective Robustness of the Continual Reassessment Method , 2010, Journal of biopharmaceutical statistics.

[7]  Shing M. Lee,et al.  Model calibration in the continual reassessment method , 2009, Clinical trials.

[8]  Ying Yuan,et al.  Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .

[9]  J O'Quigley,et al.  Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.

[10]  Ying Kuen Cheung,et al.  A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method , 2002, Biometrics.

[11]  J O'Quigley,et al.  Continual reassessment method: a likelihood approach. , 1996, Biometrics.

[12]  A. Oza,et al.  Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Alan E. Gelfand,et al.  Model choice: A minimum posterior predictive loss approach , 1998, AISTATS.